We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Crosswalk study on blood collection‐tube types for Alzheimer's disease biomarkers.
- Authors
Jonaitis, Erin M.; Zetterberg, Henrik; Koscik, Rebecca Langhough; Betthauser, Tobey J.; Van Hulle, Carol A.; Hogan, Kirk; Hegge, Laura; Kollmorgen, Gwendlyn; Suridjan, Ivonne; Gleason, Carey E.; Engelman, Corinne D.; Okonkwo, Ozioma C.; Asthana, Sanjay; Bendlin, Barbara B.; Carlsson, Cynthia M.; Johnson, Sterling C.; Blennow, Kaj
- Abstract
Introduction: Blood‐based Alzheimer's disease (AD) biomarkers show promise, but pre‐analytical protocol differences may pose problems. We examined seven AD blood biomarkers (amyloid beta [Aβ]42${\rm{A\beta }}]{_{42}}$, Aβ40${\rm{A}}{{{\beta}}_{40}}$, phosphorylatedtau[p−tau181${\rm{phosphorylated\;tau\;[p - ta}}{{\rm{u}}_{181}}$, total tau [t‐tau], neurofilament light chain [NfL], Aβ4240,${\rm{A}}{{{\beta}}_{\frac{{42}}{{40}}}},$ and p−tau181Aβ42$\frac{{{\rm{p - ta}}{{\rm{u}}_{181}}}}{{{\rm{A}}{{{\beta}}_{42}}}}$) in three collection tube types (ethylenediaminetetraacetic acid [EDTA] plasma, heparin plasma, serum). Methods: Plasma and serum were obtained from cerebrospinal fluid or amyloid positron emission tomography‐positive and ‐negative participants (N = 38) in the Wisconsin Registry for Alzheimer's Prevention. We modeled AD biomarker values observed in EDTA plasma versus heparin plasma and serum, and assessed correspondence with brain amyloidosis. Results: Results suggested bias due to tube type, but crosswalks are possible for some analytes, with excellent model fit for NfL (R2${{\rm{R}}^2}\;$= 0.94), adequate for amyloid (R2${{\rm{R}}^2}\;$= 0.40‐0.69), and weaker for t‐tau (R2${{\rm{R}}^2}\;$= 0.04‐0.42) and p−tau181${\rm{p - ta}}{{\rm{u}}_{181}}$ (R2${{\rm{R}}^2}\;$= 0.22‐0.29). Brain amyloidosis differentiated several measures, especially EDTA plasma pTau181Aβ42$\frac{{{\rm{pTa}}{{\rm{u}}_{181}}}}{{{\rm{A}}{\beta _{42}}}}$ (d$d\;$= 1.29). Discussion: AD biomarker concentrations vary by tube type. However, correlations for some biomarkers support harmonization across types, suggesting cautious optimism for use in banked blood.
- Subjects
ALZHEIMER'S disease; TAU proteins; BLOOD grouping &; crossmatching; BLOOD banks; BIOMARKERS
- Publication
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2022, Vol 14, Issue 1, p1
- ISSN
2352-8729
- Publication type
Article
- DOI
10.1002/dad2.12266